Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by canadafanon Apr 26, 2023 12:01pm

195 Views

Post# 35414752

RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

Most importantly.
There is no way, Onc would elevate the results to a verbal presentation if it was not good news.
Bad news would be downplayed.

where it goes form there ( May 25th poster reveal), June 3 presentation?
depends on many variable.
being FDA input, potential partner ( co therapy), input.
Few appreciate, the data ( Pelareorep & its abilities), is what drives .....everything.
We wil know much more in 30 days, after a long period of little updates.
all the best to everyone
regardss
cf